Kwality Pharmaceuticals Ltd · BSE:KPL
Kwality Pharmaceuticals — Investor Presentation (May 2024)
14 slides from Kwality Pharmaceuticals's investor presentation, May 27, 2024
Slide 1: Investor presentation filing letter to BSE
CIN No. L24232PB1983PLC005426 GST No. 03AAACK6458M1ZB Phone 1 91-8558820862 (Accounts) 1 91-8558820863 (Admin.) D.L. No. 1800-OSP, 1804-B I.E. Code No. 1293001210 : 91-9915743720 (Exports) KWALITY PHARMACEUTICALS LIMITED M.D. Mobile : 91-9814071215, 9814052314 E-mail : export@kwalitypharma.com Regd.
Slide 2: Disclaimer
DISCLAIMER Some of the statements made in this presentation are forward-looking statements and are based on the current beliefs, assumptions, expectations, estimates, objectives and projections of the directors and management of Kwality Pharmaceutical Limited about its business, the industry and mar
Slide 3: Kwality Pharma – At a Glance
K W A L I T Y P H A R M A – AT A G L A N C E 459.7 Total Revenue CAGR 9 years - 22% Manufacturing Setup 4 years - 21% About Kwality Pharma 307 Have 5 Formulation Units 263.6 253.9 • 3 Units in Amritsar, Punjab • Catering to a wide range of Pharmaceutical Products • 2 Units in Jassur, Himachal Prades
Slide 4: Business Model
BUSINESS MODEL Manufacturing • Each of the 5 manufacturing units have both injectables and OSD capabilities Plants • Manufacturing all type of products including complex molecules across all dosage forms including niche Biologics Product • Product portfolio of more than 3000+ formulations across 25+
Slide 5: Promoters Profile
PROMOTERS PROFILE Mr. Ramesh Arora, Managing Director Ramesh Arora is a highly regarded figure in the pharmaceutical industry with an extensive experience. His visionary leadership has propelled Kwality Pharma Ltd to new heights, establishing it as a trusted name in the international market. Today,
Slide 6: Company's Timeline
C O M PA N Y ' S T I M E L I N E . • Started Marketing Office in 2017. 2018. 2019 • New Cephalosporin facility in HP 2010 Africa • Setup of new manufacturing in HP • PICs/GMP from Iran, Iraq & Tanzania • Upgraded Oncology facility Unit 3 in HP • New manufacturing with OSD and Injectable • Upgraded G
Slide 7: Regulatory Approvals
R E G UL ATORY A P P ROVA L S Five Manufacturing Units Across Two Locations Regulatory Approvals Already Received Jassur, HP Amritsar, PB Importance of Approvals –A testimony to KPL manufacturing capabilities • While exporting any pharmaceutical product, there are two types of approvals that may be
Slide 8: Manufacturing Setup
M A N U FA C T U R I N G S E T U P Amritsar Facility Biologics Admin Block / R&D Unit 6 Multiple Therapies Betalectam & Anti-infectives Utilities Multiple Therapies Unit1 Block A Unit1 Block W Unit-2 Himachal Facility Cephalosporin Unit 4 Cytotoxic Admin Unit 3 Block 7
Slide 9: Manufacturing Setup
M A N U FA C T U R I N G S E T U P Locations Amritsar, Punjab Jassur, Himachal Pradesh Unit-1 Unit-2 Unit 5 Unit-6 Unit-3 Unit-4 Unit Names *Construction Block A & Block W1 commenced Establishment 2017 (Upgraded) FY26 Estimated FY22 FY24 FY18 FY19 Year 2007 (First Built) Critical Care, Anaesthesia,
Slide 10: Differentiated Capabilities
D I F F E R E N T I AT E D C A PA B I L I T I E S Complex injectable drug products Key Technologies Involved Key Products Developed • Tissue targeting Developed complex oncology injectables with stability data of 24 months such as Liposomal Pegylated Injectables • Intracellular targeting Doxorubicin
Slide 11: Key Markets by Sales – Region Wise (FY24)
KEY MARKETS BY SALES Sales – Region Wise (FY24) Latam - 60% Africa - 13% Asia - 10% GCC - 12% South and Central CIS / EU - 5% Africa Middle East Asia America Botswana Uganda Colombia Costa Rica South Iran Egypt India Uzbekistan Sales – Region Wise Guatemala Kenya Iraq Algeria Sri Lanka Indonesia El
Slide 12: Future Plans
FUTURE PLANS Strategic Goals 1. Leveraging the excellence in manufacturing to enter the global stringent regulated markets 2. Building long terms commercial partnerships both locally & globally 3. Focus on niche high margin portfolio of difficult to manufacture / register molecules 4. Increasing R&D
Slide 13: Key Financials
KEY FINANCIALS (Rupees in Crore) (Rupees in Crore) BALANCE SHEET FY20 FY 21 FY 22 FY 23 FY 24 Income Statement FY20 FY21 FY22 FY23 FY24 +Revenue from Ops (Gross) 139.3 262.0 456.2 251 307.2 LIABILITIES 132.69 166.26 340.59 353.63 394.21 +Other Income 3.66 1.59 3.51 2.9 1.83 Shareholders' fund 46.01
Slide 14: Thank You
THA NK YOU Kwality Pharmaceuticals Limited Head Office Address: 6th Milestone, Majitha Road, Amritsar-143601, Punjab, India Email: cs@kwalitypharma.com info@kwalitypharma.com 15
Kwality Pharmaceuticals — Investor Presentation (May 2024) on 6ix